LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

NASDAQ: LABT · HEALTHCARE · BIOTECHNOLOGY

$2.95

-4.60% today

Updated 2026-06-02

Market cap

$6.21M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.26

Dividend yield

—

52W range

$1 – $10

Volume

2.5M

Market cap

$6.21M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.26

Dividend yield

—

52W range

$1 – $10

Volume

2.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.0

Quality

C+

3.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$12.00

+306.78%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

Key financials

Revenue Net Income Free Cash Flow

Metric	TTM
Revenue	—
Net income	—
EPS	$-3.26
Free cash flow	—
Profit margin	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LABT	$6.21M	17	4.3	3.5	5.0	5.0	—	Avoid
LLY	$1.01T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$567.28B	57	4.7	9.0	3.3	6.0	-67.79%	Buy
ABBV	$391.50B	63	4.0	8.0	4.0	5.0	-48.06%	Buy
UNH	$373.28B	54	5.3	5.5	4.0	5.5	-24.80%	Buy
NVS	$289.19B	49	3.3	9.0	3.3	4.5	-62.62%	Hold

Smart narrative

Lakewood-Amedex Biotherapeutics Inc. Common Stock trades at $2.95. Our Smart Value Score of 17/100 indicates the stock is weak.

Frequently asked questions

What is Lakewood-Amedex Biotherapeutics Inc. Common Stock's stock price?

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) trades at $2.95.

Is Lakewood-Amedex Biotherapeutics Inc. Common Stock overvalued?

Lakewood-Amedex Biotherapeutics Inc. Common Stock carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)?

The 12-month analyst consensus target is $12.00, about 306.8% above the current $2.95. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$18.09

200D MA$18.09

Shares out0.00B

Float0.00B

Short ratio—

Avg volume2.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

LABT vs LLY →LABT vs JNJ →LABT vs ABBV →Stock screener →